Gilead Sciences (GILD) Net Cash Flow (2009 - 2026)
Gilead Sciences' (GILD) quarterly Net Cash Flow came in at $75.0 million in Q1 2026, up 103.6% YoY from $36.8 million in Q1 2025, and down 67.25% on a QoQ basis from $229.0 million in Q4 2025.
Gilead Sciences (GILD) Net Cash Flow (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Net Cash Flow data on file, last reported at $75.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 103.6% year-over-year to $75.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$360.0 million (down 111.21% YoY) and the FY2025 annual result came in at -$2.5 billion, down 163.84% from the prior year.
- Net Cash Flow fell to $75.0 million in Q1 2026, from $229.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $5.0 billion in Q4 2024 to a low of -$2.9 billion in Q2 2025.
- A 5-year average of $132.6 million and a median of $75.0 million in 2026 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 31614.29% in 2024, down 356.63% in 2024.
- Tracing GILD's Net Cash Flow over 5 years: stood at $638.0 million in 2022, then sank by 46.24% to $343.0 million in 2023, then soared by 1360.64% to $5.0 billion in 2024, then slumped by 95.43% to $229.0 million in 2025, then tumbled by 67.25% to $75.0 million in 2026.
- The last three Net Cash Flow figures came in at $75.0 million (Q1 2026), $229.0 million (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.71 Bn | 632.95 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.97 Bn | 463.40 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 375.96 Bn | 368.82 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 304.06 Bn | 296.37 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.78 Bn | 252.88 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 236.52 Bn | 222.53 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.34 Bn | 102.17 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.19 Bn | 47.81 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.43 Bn |
| Jun 30, 2026 | -4.43 Bn |
| Mar 31, 2026 | 75.00 Mn |
| Mar 31, 2026 | 75.00 Mn |
| Dec 31, 2025 | 229.00 Mn |
| Dec 31, 2025 | 229.00 Mn |
| Sep 30, 2025 | 2.19 Bn |
| Sep 30, 2025 | 2.19 Bn |
| Jun 30, 2025 | -2.86 Bn |
| Jun 30, 2025 | -2.86 Bn |
| Mar 31, 2025 | -2.08 Bn |
| Mar 31, 2025 | -2.08 Bn |
| Dec 31, 2024 | 5.01 Bn |
| Dec 31, 2024 | 5.01 Bn |
| Sep 30, 2024 | 2.22 Bn |
| Sep 30, 2024 | 2.22 Bn |
| Jun 30, 2024 | -1.94 Bn |
| Jun 30, 2024 | -1.94 Bn |
| Mar 31, 2024 | -1.35 Bn |
| Mar 31, 2024 | -1.35 Bn |